Antiproliferative Effect Of Above-Label Doses Of Somatostatin Analogs For The Management Of Gastroenteropancreatic Neuroendocrine Tumors

Leonidas Diamantopoulos, Faidon-Marios Laskaratos, Markos Kalligeros, Ruchir Shah, Shaunak Navalkissoor, Gopinath Gnanasegaran, Jamie Banks, Jack Smith, Benjamin Jacobs, Michail Galanopoulos, Dalvinder Mandair, Martyn Caplin, Christos Toumpanakis
Neuroendocrinology 2020 June 15

INTRODUCTION: Above-label doses of somatostatin analogs (SSAs) are increasingly utilized in the management of inoperable/metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), progressing on standard 4-weekly regimens.

OBJECTIVE: To evaluate the antiproliferative effect of 3-weekly SSA administration in a retrospective GEP-NETs cohort.

METHODS: Patients with advanced GEP-NETs, treated with long acting release (LAR) octreotide 30mg or lanreotide Autogel 120mg at a 3-weekly interval, after disease progression on standard 4-weekly doses, were retrospectively identified. Clinicopathologic and treatment response data were collected. Progression-free survival (PFS - dose escalation to radiographic progression or death) was estimated with the Kaplan - Meier method. Factors associated with PFS were identified with the Cox proportional-hazards model.

RESULTS: Inclusion criteria were fulfilled by 105 patients. Octreotide LAR was administered to 60 (57%) and lanreotide Autogel to 45 (43%). Indications for dose escalation were breakthrough carcinoid symptoms (58%), radiographic progression (35%) and/or increasing biomarkers (11%). Diarrheal and/or flushing symptomatic improvement was identified in 37/67 (55%) and 30/55 cases (55%) with available data, respectively. Disease control rate (radiographic partial response or stable disease) was achieved in 53 patients (50%). Median PFS was 25.0 months (95% CI: 16.9 - 33.1). Patients with radiographic progression <12 months from 4-weekly SSA initiation had worse PFS after dose escalation (7.0 vs. 17.0 months, p = 0.002). In multivariate analysis, pancreatic NETs, Ki-67≥5% and multiple extrahepatic metastases were independently associated with inferior PFS.

CONCLUSIONS: Above-label doses of SSAs may offer a considerable prolongation in PFS and could be utilized as a bridge to other more toxic treatments. Patients with small bowel/colorectal primaries, Ki-67<5% and absence of/limited extrahepatic metastases are more likely to benefit from this approach.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"